Hypoxystat
Hypoxystat increases the affinity of hemoglobin for oxygen and reduces the release of oxygen to tissues, thereby inducing the tissue hypoxia. Hypoxystat alleviates the mitochondrial disease Leigh syndrome in Ndufs4 knockout mouse models. Hypoxystat exhibits orally activity[1].
Product Specifications
CAS Number
2414508-40-8
UNSPSC
12352005
Target
Reactive Oxygen Species (ROS)
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Others
Purity
99.28
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N1CCCC[C@H]1COC2=CC=CC(O)=C2C=O)C3=C(C=O)C=CC=C3
Molecular Formula
C21H21NO5
Molecular Weight
367.40
References & Citations
[1]Blume SY, et al., HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity. Cell. 2025 Feb 12:S0092-8674 (25) 00098-4.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15365918 1 Vial
Lentiviral human BNC2 sgRNA gene knockout kit - Lentiviral human BNC2 sgRNA gene knockout kit (plasmid)
Sign In for Pricing
View Details 
UFC04015-01 50 mg
6-Chloro-7,8-dimethyl-3- (trifluoromethyl) -[1,2,4]triazolo[4,3-b]pyridazine
Sign In for Pricing
View Details